Noninvasive diagnosis and pharmacotherapy of metabolic dysfunction-associated steatotic liver disease
10.12206/j.issn.2097-2024.202403049
- VernacularTitle:代谢相关脂肪性肝病的无创诊断与药物治疗
- Author:
Danni SUN
1
;
Yong HUANG
1
;
Jiabao ZHANG
1
;
Pei WANG
1
Author Information
1. Department of Pharmacology, School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
metabolic dysfunction-associated steatotic liver disease;
metabolic associated steatohepatitis;
biomarkers;
pharmacotherapy
- From:
Journal of Pharmaceutical Practice and Service
2024;42(10):411-418
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated steatotic liver disease （MASLD） is the most prevalent chronic liver disease globally, encompassing the entire spectrum of fatty liver pathogenesis. It progresses from simple steatosis to metabolic-associated steatohepatitis （MASH）, involving injury and inflammation，with or without fibrosis，ultimately leading to cirrhosis and hepatocellular carcinoma, which affects approximately a quarter of the world's population. Liver biopsy remains the gold standard for differentiating MASH from steatosis and assessing advanced fibrosis. However, its limitations, including costliness, invasiveness, and sampling bias, have spurred the development of noninvasive diagnostic techniques. In addition, there are no FDA-approved drugs for the treatment of MASLD. Enumerating noninvasive diagnostic markers that have the potential to replace liver biopsy were summarized, and the current treatment options for MASLD were discussed, with clinical trials designed to evaluate the efficacy and safety of single agents or combination therapies to halt or reverse disease progression, which could provide new insights for the clinical diagnosis and treatment of MASLD.
